Showing results (121-130 of 219) with videos related to
Sort By:
Pageof 22
American Journal of Translational Research|September 10, 2011
Network modeling of CDF treated pancreatic cancer cells reveals a novel c-myc-p73 dependent apoptotic mechanismAsfar S Azmi, Shadan Ali, Sanjeev Banerjee, et al.American Journal of Clinical Oncology|October 7, 2006
A phase II study of docetaxel, doxorubicin, and infusional 5-fluorouracil in the treatment of patients with locally advanced breast cancerLata Chandi Thatai, Priya Vishnubhotla, Laura Biernat, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 1, 2006
Phase II study of erlotinib in patients with advanced biliary cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2005
Phase II study of Erlotinib (OSI-774) in patients with advanced hepatocellular cancerPhilip A Philip, Michelle R Mahoney, Cristine Allmer, et al.Cancer Treatment Reviews|June 5, 2019
Optimizing the management of locally advanced pancreatic cancer with a focus on induction chemotherapy: Expert opinion based on a review of current evidenceThomas Seufferlein, Pascal Hammel, Jean Robert Delpero, et al.Oncology|October 18, 2017
An Intergroup Randomized Phase II Study of Bevacizumab or Cetuximab in Combination with Gemcitabine and in Combination with Chemoradiation in Patients with Resected Pancreatic Carcinoma: A Trial of the ECOG-ACRIN Cancer Research Group (E2204)Jordan D Berlin, Yang Feng, Paul Catalano, et al.Cancer Metastasis Reviews|April 20, 2021
Gastrointestinal stromal tumor: a review of current and emerging therapiesBayan Al-Share, Abdulrahman Alloghbi, Mohammed Najeeb Al Hallak, et al.Signal Transduction and Targeted Therapy|November 27, 2025
Targeting KRAS mutations: orchestrating cancer evolution and therapeutic challengesKhalil Choucair, Hafsa Imtiaz, Md Hafiz Uddin, et al.Oncotarget|November 16, 2017
Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migrationAsfar S Azmi, Yiwei Li, Irfana Muqbil, et al.European Journal of Cancer (Oxford, England : 1990)|February 17, 2010
MDM2 inhibitor MI-319 in combination with cisplatin is an effective treatment for pancreatic cancer independent of p53 functionAsfar S Azmi, Amro Aboukameel, Sanjeev Banerjee, et al.Pageof 22